ENDRA Life Sciences (NDRA) Total Non-Current Liabilities (2019 - 2026)

ENDRA Life Sciences (NDRA) has reported Total Non-Current Liabilities for 8 consecutive years, with $845936.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 11.62% year-over-year to $845936.0 in Q2 2026; TTM through Jun 2026 was $845936.0, a 11.62% increase from a year earlier, with the FY2025 full-year figure at $842721.0, down 34.51% from the prior year.
• Total Non-Current Liabilities was $845936.0 for Q2 2026 at ENDRA Life Sciences, up from $815857.0 in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.3 million in Q4 2024 and troughed at $98421.0 in Q2 2024.
• A 5-year average of $645637.1 and a median of $815857.0 in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 47.51% in 2023 and surged 670.04% in 2025, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $365919.0 in 2022, then plunged by 47.51% to $192062.0 in 2023, then soared by 569.97% to $1.3 million in 2024, then sank by 34.51% to $842721.0 in 2025, then gained by 0.38% to $845936.0 in 2026.
• The last three Total Non-Current Liabilities figures came in at $845936.0 (Q2 2026), $815857.0 (Q1 2026), and $842721.0 (Q4 2025), per Business Quant data.